(BLCO) Bausch + Lomb - Ratings and Ratios
Contacts, Drops, Drugs, Vitamins, Surgery
BLCO EPS (Earnings per Share)
BLCO Revenue
Description: BLCO Bausch + Lomb July 28, 2025
Bausch + Lomb Corporation is a leading eye health company operating globally, with a presence in over 15 countries. The companys diversified portfolio spans three main segments: Vision Care, Pharmaceuticals, and Surgical, catering to various eye care needs, from contact lenses and eye drops to surgical equipment and pharmaceuticals for post-operative care and treatment of eye diseases.
The Vision Care segment is a significant contributor, offering a range of contact lenses, including daily disposables and therapeutic lenses, as well as eye care products like vitamins, supplements, and over-the-counter drops for conditions such as dry eye and allergies. The Pharmaceuticals segment provides both proprietary and generic products for treating glaucoma, ocular hypertension, and retinal diseases, among others. The Surgical segment is equipped with advanced technologies for cataract surgery, including intraocular lenses and phacoemulsification equipment.
From a performance perspective, key metrics to watch include revenue growth across segments, particularly in emerging markets, and the success of new product launches. The companys ability to expand its product offerings through innovation and strategic acquisitions is crucial. Operational efficiency, including the management of sales forces and distribution networks, will also be important. Key Performance Indicators (KPIs) to monitor include gross margin ratio, operating margin, and return on equity (ROE), which currently stands at -7.56%, indicating a need for improvement. Other relevant KPIs include the debt-to-equity ratio and the interest coverage ratio to assess the companys financial health and leverage.
Given the companys history and global presence, Bausch + Lombs competitive positioning within the eye health industry is strong, with a broad product portfolio. However, the negative ROE and lack of a reported P/E ratio suggest challenges in profitability. Investors should closely watch the forward P/E ratio of 20.96 and monitor the companys progress in improving its bottom line. The current market cap of $4936.70M USD indicates a significant market presence, and the stocks technical indicators, such as moving averages, may provide insights into its price momentum and potential future movements.
BLCO Stock Overview
| Market Cap in USD | 5,078m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 2022-05-06 |
BLCO Stock Ratings
| Growth Rating | -28.7% |
| Fundamental | 43.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -33.4% |
| Analyst Rating | 3.53 of 5 |
BLCO Dividends
Currently no dividends paidBLCO Growth Ratios
| Growth Correlation 3m | 66.8% |
| Growth Correlation 12m | -65.2% |
| Growth Correlation 5y | -26.7% |
| CAGR 5y | 2.10% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.04 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.11 |
| Sharpe Ratio 12m | -0.51 |
| Alpha | -35.26 |
| Beta | 0.631 |
| Volatility | 37.44% |
| Current Volume | 306.1k |
| Average Volume 20d | 401.6k |
| Stop Loss | 15.1 (-3.9%) |
| Signal | 0.38 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-401.0m TTM) > 0 and > 6% of Revenue (6% = 293.2m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -0.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 20.59% (prev 24.32%; Δ -3.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 186.0m > Net Income -401.0m (YES >=105%, WARN >=100%) |
| Net Debt (4.69b) to EBITDA (351.0m) ratio: 13.35 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (353.7m) change vs 12m ago 0.54% (target <= -2.0% for YES) |
| Gross Margin 58.17% (prev 57.55%; Δ 0.62pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.09% (prev 33.92%; Δ 2.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.06 (EBITDA TTM 351.0m / Interest Expense TTM 420.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.00
| (A) 0.07 = (Total Current Assets 2.85b - Total Current Liabilities 1.84b) / Total Assets 13.83b |
| (B) -0.06 = Retained Earnings (Balance) -845.0m / Total Assets 13.83b |
| (C) 0.00 = EBIT TTM 25.0m / Avg Total Assets 13.54b |
| (D) -0.28 = Book Value of Equity -2.04b / Total Liabilities 7.32b |
| Total Rating: -0.00 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.11
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -1.69% = -0.84 |
| 3. FCF Margin -3.38% = -1.27 |
| 4. Debt/Equity 0.77 = 2.21 |
| 5. Debt/Ebitda 13.35 = -2.50 |
| 6. ROIC - WACC (= -4.64)% = -5.79 |
| 7. RoE -6.20% = -1.03 |
| 8. Rev. Trend 88.79% = 6.66 |
| 9. EPS Trend -46.43% = -2.32 |
What is the price of BLCO shares?
Over the past week, the price has changed by +4.94%, over one month by +3.02%, over three months by +9.86% and over the past year by -22.80%.
Is Bausch + Lomb a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BLCO is around 15.07 USD . This means that BLCO is currently overvalued and has a potential downside of -4.07%.
Is BLCO a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the BLCO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.3 | -2.6% |
| Analysts Target Price | 15.3 | -2.6% |
| ValueRay Target Price | 16.2 | 3.3% |
BLCO Fundamental Data Overview October 12, 2025
P/E Forward = 13.3869
P/S = 1.0383
P/B = 0.811
P/EG = 0.6992
Beta = 0.631
Revenue TTM = 4.89b USD
EBIT TTM = 25.0m USD
EBITDA TTM = 351.0m USD
Long Term Debt = 4.93b USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last quarter)
Debt = 4.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.69b USD (from netDebt column, last quarter)
Enterprise Value = 9.77b USD (5.08b + Debt 4.96b - CCE 272.0m)
Interest Coverage Ratio = 0.06 (Ebit TTM 25.0m / Interest Expense TTM 420.0m)
FCF Yield = -1.69% (FCF TTM -165.0m / Enterprise Value 9.77b)
FCF Margin = -3.38% (FCF TTM -165.0m / Revenue TTM 4.89b)
Net Margin = -8.21% (Net Income TTM -401.0m / Revenue TTM 4.89b)
Gross Margin = 58.17% ((Revenue TTM 4.89b - Cost of Revenue TTM 2.04b) / Revenue TTM)
Gross Margin QoQ = 58.92% (prev 57.46%)
Tobins Q-Ratio = 0.71 (Enterprise Value 9.77b / Total Assets 13.83b)
Interest Expense / Debt = 2.58% (Interest Expense 128.0m / Debt 4.96b)
Taxrate = 60.54% (-89.0m / -147.0m)
NOPAT = 9.86m (EBIT 25.0m * (1 - 60.54%))
Current Ratio = 1.55 (Total Current Assets 2.85b / Total Current Liabilities 1.84b)
Debt / Equity = 0.77 (Debt 4.96b / totalStockholderEquity, last quarter 6.44b)
Debt / EBITDA = 13.35 (Net Debt 4.69b / EBITDA 351.0m)
Debt / FCF = -28.41 (negative FCF - burning cash) (Net Debt 4.69b / FCF TTM -165.0m)
Total Stockholder Equity = 6.47b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.90% (Net Income -401.0m / Total Assets 13.83b)
RoE = -6.20% (Net Income TTM -401.0m / Total Stockholder Equity 6.47b)
RoCE = 0.22% (EBIT 25.0m / Capital Employed (Equity 6.47b + L.T.Debt 4.93b))
RoIC = 0.09% (NOPAT 9.86m / Invested Capital 11.27b)
WACC = 4.72% (E(5.08b)/V(10.04b) * Re(8.34%) + D(4.96b)/V(10.04b) * Rd(2.58%) * (1-Tc(0.61)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.29%
Fair Price DCF = unknown (Cash Flow -165.0m)
EPS Correlation: -46.43 | EPS CAGR: -10.90% | SUE: -0.71 | # QB: 0
Revenue Correlation: 88.79 | Revenue CAGR: 11.73% | SUE: 0.05 | # QB: 0
Additional Sources for BLCO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle